ライフサイエンスコーパス: hepatitis A vaccine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 who responded to a 3-dose primary series of hepatitis A vaccine.

2 l subjects reported a willingness to receive hepatitis A vaccine.

3 iting fewer injection-site symptoms than the hepatitis A vaccine (19.8% compared with 37.5%).

4 ere vaccinated with two doses of inactivated hepatitis A vaccine, 6 months apart.

5 Persistence of seropositivity conferred by hepatitis A vaccine administered to children <2 years of

6 Hepatitis A vaccine administered to persons after exposu

7 Among these contacts, 568 received hepatitis A vaccine and 522 received immune globulin.

8 s A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separa

9 of hepatitis A in both groups indicate that hepatitis A vaccine and immune globulin provided good pr

10 Hepatitis A vaccines are highly immunogenic in healthy p

11 60 children with 162 household contacts, and hepatitis A vaccine as a control was administered to 67

12 s an adjuvant; control subjects received the hepatitis A vaccine, at a dose of 720 enzyme-linked immu

13 ricomponent acellular pertussis vaccine or a hepatitis A vaccine (control) and were monitored for 2.5

14 age, in a 1:1 ratio, to receive the QIV or a hepatitis A vaccine (control).

15 The seropositivity induced by hepatitis A vaccine given to children <2 years of age pe

16 ized into three groups to receive a two-dose hepatitis A vaccine: group 1 at 6 and 12 months, group 2

17 Since the mid-1990s, hepatitis A vaccine has been recommended for US children

18 Hepatitis A vaccine has similar efficacy to immune globu

19 combined with the availability of effective hepatitis A vaccines have dramatically reduced the burde

20 rus, pneumococcal, polio, meningococcal, and hepatitis A vaccines have taken place, which will have m

21 In this study, AE profiles induced by hepatitis A vaccine (Havrix), hepatitis B vaccine (Enger

22 ssess the safety and efficacy of inactivated hepatitis A vaccine in OLT recipients.

23 safety and immunogenicity of an inactivated hepatitis A vaccine in patients with CLD with that in he

24 ase have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven.

25 The response to the hepatitis A vaccine is optimal when targeted to patients

26 SmithKline, Rixensart, Belgium) or a control hepatitis A vaccine (modified preparation of Havrix, Gla

27 04 candidate vaccine (n = 1088) or a control hepatitis A vaccine (n = 1101) over 6 months.

28 tivized measures (largest difference was for hepatitis A vaccine: odds ratio, 0.34; 99.88% CI, 0.31-0

29 receive one standard age-appropriate dose of hepatitis A vaccine or immune globulin within 14 days af

30 , the first dose was 720 ELISA units (EU) of hepatitis A vaccine, readministered at 1 and 12 months a

31 3%) seroconverted after a single dose of the hepatitis A vaccine than did subjects with chronic hepat

32 (n = 70) 4 weeks after a dose of inactivated hepatitis A vaccine (VAQTA).

33 gned (1:1) to HPV-16/18 vaccine or a control hepatitis A vaccine, via an internet-based central rando

34 25-, 50-, and 100-U doses of an inactivated hepatitis A vaccine was examined in 358-seronegative vol

35 In this population, hepatitis A vaccine was highly effective in preventing d

36 In conclusion, hepatitis A vaccine was well tolerated and induced a sat

37 y objective was to compare the safety of the hepatitis A vaccine with that of a commercial hepatitis

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。